Dori Thomas-Karyat

Founder & Chief Executive Officer Synthis Therapeutics, Inc

Dr. Dori Thomas-Karyat is the Founder and CEO of Synthis Therapeutics, where she leads the development of a first-in-class ADC platform targeting TGF-ß-driven diseases, including fibrotic disorders such as IPF. A recognized expert in TGF-ß biology with over 20 years of experience in oncology, fibrosis, and immuno-oncology, she has held leadership roles in drug discovery at AbbVie and Roche. Dr. Thomas-Karyat completed her postdoctoral fellowship at Memorial Sloan Kettering Cancer Center in the lab of TGF-ß pioneer Dr. Joan Massagué and holds a Ph.D. in Immunology from Washington University School of Medicine in St. Louis. She has been awarded multiple SBIR grants, holds six issued patents, and is a frequent speaker at scientific conferences.

Seminars

Thursday 19th March 2026
Unlocking the Potential of Novel Bioconjugates in Neurology & Rare Disease
12:30 pm
  • Leveraging small-format and peptide conjugates for BBB penetration
  • Assessing preclinical models for neuro-targeted delivery
  • Evaluating payload compatibility for CNS indications
Dori Thomas-Karyat - 5th Novel Conjugates Summit
View all Speakers
View Event Brochure